



September 30, 2019
Repertoire Genesis Inc.

Notice Regarding Joint R & D Agreement and Capital Alliance with Zenyaku Kogyo Co., Ltd.

Repertoire Genesis Inc. (Headquarters: Ibaraki, Osaka, hereinafter "Repertoire Genesis") entered into a joint R&D agreement and capital alliance with Zenyaku Kogyo Co., Ltd. (Headquarters: Bunkyo-ku, Tokyo, hereinafter "Zenyaku").

In this joint research and development agreement, we will harness the therapeutic drug, clinical development know-how and research network owned by Zenyaku, with immune diversity analysis technology and intellectual property such as TCR/BCR repertoire analysis and Neoepitope analysis and research network owned by Repertoire Genesis. We will elucidate the involvement of the immune system in various diseases in detail. In addition, we will contribute to the health of people around the world by jointly developing novel diagnostic/therapeutic methods.

In addition, Repertoire Genesis has formed a capital alliance with Zenyaku mainly for the purpose of accelerating research and development. Through this capital alliance, the two companies will build a medium- to long-term strategic relationship.

Repertoire Genesis will continue to promote further improvement and application of its unique immune diversity analysis technology including TCR/BCR repertoire analysis. In addition, by focusing on cutting-edge R&D and businesses necessary to protect world people's health, we will contribute to elucidating the mechanisms of diseases and accelerating the development of novel diagnostic and treatment methods.



About Repertoire Genesis

Repertoire Genesis is a Japanese biotechnology company dedicated to developing novel immune related treatment and diagnostics based on its corporate mission of “curing the incurable”. We take an approach to analyze the immune system in detail based on our unique immune diversity analysis technology such as TCR/BCR repertoire analysis and neoepitope analysis. Since our establishment in October 2014, we continue to challenge to provide effective treatments and diagnostics for unresolved medical needs specifically focusing on cancer, autoimmune and infectious diseases.

For further information, contact:

Administrative department, Repertoire Genesis Inc.

Tokyo Office: Nihonbashi Life Science Building 2 703, 3-11-5 Nihonbashi honcho, Chuo-ku, Tokyo, 103-0023 Japan

Email: ir@repertoire.co.jp

URL: <https://www.repertoire.co.jp/en/>